Skip to main content
. 2020 Feb 12;19:17. doi: 10.1186/s12933-020-0990-2

Fig. 3.

Fig. 3

Comparisons of glycemic and pleiotropic effects between SGLT2 inhibitors and DPP4 inhibitors in patients with different eGFR levels. a Baseline eGFR < 60 ml/min/1.73m2. b Baseline eGFR ≥ 60 ml/min/1.73m2